Citi Cuts Tasly Pharmaceutical Revenue and EPS Estimates
Citi analysts cite tighter hospital controls on traditional Chinese medicine injections and weaker cold-medicine demand. They cut revenue estimates by 4% for 2026 and 6% each for 2027 and 2028, and EPS estimates by 3% for t…